

Ipsen Public Policy Activities Statement

Introduction

At Ipsen, we believe we have a role in shaping public policy and regulatory frameworks fit for purpose. By engaging in dialogue with policymakers and policy stakeholders, organizations like Ipsen can work collaboratively to develop policies that foster innovation and address the high unmet needs of patients. Through these efforts, we can ensure that the voices of multiple stakeholders are heard, leading to more informed decision-making and the creation of environments that support the delivery of cutting-edge healthcare solutions. This collaborative approach is essential for driving progress and delivering meaningful advancements for patients and public health.

Our approach

At Ipsen, our mission is to improve patients' lives. We engage in health policy advocacy with a steadfast commitment to transparency, integrity, and compliance with all applicable laws and regulations. Our efforts are dedicated to informing and engaging in public policy debates to enhance patient care and support the advancement of the innovation framework to address our patients' unmet needs. Ipsen strictly adheres to anti-corruption laws and regulations. We do not offer anything of value to obtain favorable treatment or inappropriately influence policymakers. Our compliance with these principles is unwavering, and we take any violations seriously.

Our general principles

- We operate transparently and in compliance with the laws, regulations and codes on interactions with policy makers, and driven by the highest ethical standards in the best interest of patients.
- We expect the policy makers we interact with to be compliant with the transparency and disclosure rules that apply to them, including those of the institutions they cooperate with.
- We provide policy makers with information that is fair, balanced and substantiated to enable them to exercise the best possible judgement in creating and implementing policies in the interest of patients and society.
- We do not influence policy makers inappropriately through misleading information or offer anything of value to obtain favorable treatment for Ipsen or its products.
- We require suppliers to adhere to our Business Partner Code of Conduct and to demonstrate their compliance through regular assessments.

Trade Association Management System

As a global biopharmaceutical actor, Ipsen is a member of different global, regional and national trade associations. To ensure consistency and respect of our commitments, we have implemented an internal management system to oversee our public policy activities and trade association memberships. This system tracks our annual monetary contributions and other political expenditures, ensuring adherence to the highest standards of ethical conduct and transparency.

Transparency and Reporting

Ipsen is committed to transparency regarding our public policy and engagement expenditures. We disclose these activities in accordance with regional and national laws, including membership dues in trade

associations. Our dedication to transparency reflects our commitment to ethical practices and our belief in the importance of contributing positively to the policy-making process. Ipsen reports public policy activities in regional and national Transparency Registers, where present.

In 2023, Ipsen's expenditures for public policy activities in regions and countries with a commercial presence¹, political contributions and trade associations were:

- We spent €1,677,085.28 on public policy activities. These activities include direct communication and contact with policymakers or regulatory institutions for the purpose of engaging and sharing our position, as well as responses to consultations and other engagements on policy initiatives. As part of the previous amount, €853,284.49 were allocated for supporting policies related to access to therapeutic innovation to combat cancer, improving post-stroke care, innovation-friendly regulatory environment, patient access to orphan drugs, addressing unmet medical needs in oncology, patient access to innovative treatments, including for rare disease patients.
- We allocated €3,979,924.26 on our membership fees to national, regional and global trade associations and other relevant non-for-profit organizations representing the pharmaceutical industry.
- Ipsen did not make any political contributions.

As we continue our political advocacy and public policy activities, Ipsen remains committed to acting with integrity and in the best interest of patients. We will continue to comply with and adapt our ways of working to ensure the highest ethical standards in our external activities.

¹ Including: Algeria, Asian-Pacific Region (South Korea, Singapore, Malaysia, Taiwan), Australia, Austria, Baltics Region, Belgium, Brazil, China, Czech Republic, Denmark, Egypt, France, Germany, Italy, Middle-East Region, Mexico, New Zealand, Poland, The Netherlands, Saudia Arabia, Sweden, Spain, Switzerland, Tunisia, United Arab Emirates, The United States, The United Kingdom. The Global department is included and covered activities above countries.